insitro

Insitro: A Data-Driven Drug Discovery CompanyInsitro is a data-driven drug discovery company that relies on machine learning and high-throughput biology technologies to transform the way drugs are discovered and delivered to patients. The company was officially established in 2018 and is located in South San Francisco, California, USA. Insitro addresses many of the current challenges in drug discovery by extensively collecting large amounts of data and analyzing it using machine learning models.Insitro does not rely solely on limited "found" data but instead uses modern biological tools to generate high-quality big datasets optimized for machine learning, enabling it to unlock the full potential of modern computational methods to develop novel drugs. At the same time, insitro has its unique culture, bringing together individuals from diverse backgrounds into one team, including life scientists and data scientists, software engineers, process engineers, and bioengineers, translational scientists, and drug hunters. Insitro's main product is the ISH platform, which applies machine learning to human genetics, functional genomics, and biology to generate and optimize unique in vitro models, driving the discovery and development of therapeutic approaches. This platform is expected to provide disease insights, suggest candidate targets, and predict patient responses to potential therapeutic interventions.The ISH platform utilizes the latest advances in bioengineering, enabling it to generate high-throughput functional genomics datasets and match them with patient data through novel machine learning approaches, building predictive models that accelerate target selection and the design of effective therapies. Specifically, the ISH platform can provide population-scale data, cell-based disease models, distinguish cell states, predict disease-related clinical features, discover disease subtypes, and offer intervention strategies. These predictive models can accelerate target selection and the design of effective therapies. Insitro’s proprietary ISH platform will be used to build disease models for NASH and identify targets affecting disease progression and recovery.